Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03600376
Recruitment Status : Recruiting
First Posted : July 25, 2018
Last Update Posted : August 9, 2019
Sponsor:
Information provided by (Responsible Party):
Eagle Pharmaceuticals, Inc.

Brief Summary:
A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) compared to current Standard of Care (SOC) for EHS.

Condition or disease Intervention/treatment Phase
Exertional Heat Stroke Drug: Ryanodex and Standard of Care Other: Standard of Care Phase 3

Detailed Description:
Following triage and primary assessment in the emergency medical facility, subjects will be randomized to 1 of 2 treatment arms, SOC plus Ryanodex or SOC only. Subjects will be dosed and followed for up to 6 hours post-randomization. Current SOC is limited to body cooling and supportive measures.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Ryanodex (dantrolene sodium) for injectable suspension plus Standard of Care
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Phase 3, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Actual Study Start Date : August 19, 2018
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : August 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Ryanodex and Standard of Care
In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.
Drug: Ryanodex and Standard of Care
Ryanodex to be administered as a rapid IV push
Other Name: Ryanodex and SOC

Standard of Care only (SOC)
Standard of Care treatment will consist of the immediate start of cooling measures.
Other: Standard of Care
Body cooling measures and supportive measures
Other Name: SOC




Primary Outcome Measures :
  1. Glasgow Coma Score (GCS) greater than or equal to 13 [ Time Frame: 90 minutes post-randomization ]
    The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).


Secondary Outcome Measures :
  1. Glasgow Coma Score (GCS) greater than or equal to 13 at planned time points [ Time Frame: Up to 6 hours post-randomization ]
    The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Core body temperature of greater than or equal to 40.0 degrees C (104 degrees F); recent history of exertional activity; GCS score less than 13; tachycardia -

Exclusion Criteria: clinical severe infection; hyperthermia secondary to another condition; endotracheal intubation;; sedative drugs administered prior to or at time of study entry; likelihood of head trauma within 6 months pre-study; positive pregnancy test; history of myocardial infection within 30 days; history of seizure disorder or epilepsy; concomitant or prior use of calcium channel blockers.

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03600376


Contacts
Layout table for location contacts
Contact: Adrian J Hepner, MD,PhD 201-326-5306 ahepner@eagleus.com

Locations
Layout table for location information
Saudi Arabia
King Faisal Hospital Recruiting
Mecca, Saudi Arabia
Contact: Sami Jabir Alsolamy, MD         
Principal Investigator: Sami Jabir Alsolamy, MD         
Mina al Jisr Hospital Recruiting
Mina, Saudi Arabia
Principal Investigator: Nawfal Aljerian, MD         
Mina Al-Shari Al-Jadeed Hospital Recruiting
Mina, Saudi Arabia
Contact: Abdulrahman Al Qahtani, MD         
Principal Investigator: Abdulrahman Al Qahtani, MD         
Mina Al-Wadi Hospital Recruiting
Mina, Saudi Arabia
Contact: Badar Sager Al Otaibi, MD         
Principal Investigator: Badar Sager Al Otaibi, MD         
Sponsors and Collaborators
Eagle Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Adrian Hepner Eagle Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Eagle Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03600376     History of Changes
Other Study ID Numbers: EGL-4104-C-1801
First Posted: July 25, 2018    Key Record Dates
Last Update Posted: August 9, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heat Stroke
Sunstroke
Heat Stress Disorders
Wounds and Injuries
Dantrolene
Muscle Relaxants, Central
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents